Mechanism of Action of Intralipid

Lipid Sink Theory

The "lipid sink" theory, initially developed to explain intralipid’s efficacy in LAST, may also apply to amniotic fluid embolism. This theory suggests that administering a lipid emulsion creates a reservoir “sink” in the bloodstream that absorbs lipophilic (fat-soluble) substances. In the context of amniotic fluid embolism, it’s hypothesized that the intralipid emulsion might sequester the toxic, lipid-soluble components present in the amniotic fluid. This sequestration reduces the concentration of these toxins in circulation, mitigating their impact on vital organs such as the heart and lungs.

Immunomodulatory Effects

The inflammatory response has a significant role in the pathophysiology of amniotic fluid embolism, and emerging evidence suggests that intralipids may possess immunomodulatory properties. In animal studies, intralipid reduced pro-inflammatory cytokine levels and increased anti-inflammatory cytokine production. This modulation of the inflammatory response could benefit amniotic fluid embolism, where anaphylactoid reactions are thought to drive the systemic inflammatory cascade.

Pulmonary Vasodilation and Hemodynamic Stabilization

The pulmonary vasoconstriction seen in amniotic fluid embolism raises right ventricular afterload and contributes to right ventricular failure and hemodynamic collapse. Prostacyclin, a potent vasodilator derived from arachidonic acid, lowers pulmonary vascular resistance, and prostacyclin analogues are used clinically for that purpose.

Lipid emulsion supplies polyunsaturated fatty acids that feed the eicosanoid pathways from which prostacyclin is produced, and it has been proposed that this contributes to pulmonary vasodilation and reduced right heart strain after a lipid bolus. The evidence for this mechanism in amniotic fluid embolism is indirect, and any vasodilatory effect would be expected to improve oxygenation and circulation.

Direct Cardioprotective Effects and Energy Metabolism

Studies have shown that intralipid has a direct cardioprotective effects and its administration in animal models improved cardiac contractility (positive inotropic effect) because it enhances fatty acid oxidation and energy metabolism in cardiac cells and improves cardiac relaxation. These findings indicate that intralipid may support cardiac function independently of the lipid sink effect. It is helpful in conditions like amniotic fluid embolism, where right ventricular failure is a common complication. 

Inhibition of Mitochondrial Permeability Transition Pore (MPTP) Opening

The MPTP is a key regulator of cell death and mitochondrial dysfunction. Studies have demonstrated that intralipids can inhibit MPTP opening, which prevents apoptosis (programmed cell death) and protects myocardial cells from damage.  

By this pore opening prevention, the intralipid may protect cardiac cells from ischemia-reperfusion injury, which leads to amniotic fluid embolism-related cardiac collapse. Additionally, intralipids have been found to activate the Akt signaling pathway, which promotes cell survival and prevents apoptosis. 

Five proposed mechanisms by which a lipid emulsion may help in amniotic fluid embolism, most supported by animal and laboratory studies.